Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Jeffrey

Showing results (641-650 of 651) with videos related to

Pageof 66
Sort By:
ACS Chemical Neuroscience|January 25, 2026
Discovery of VU6025733 (AG06827): A Highly Selective, Orally Bioavailable, and Structurally Distinct M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust <i>In Vivo</i> EfficacyAlison R Gregro, Charlotte Park, Madeline F Long, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 17, 2000
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-AC Reavill, S G Taylor, M D Wood, et al.
Journal of Medicinal Chemistry|April 13, 2022
Development of <b>VU6019650</b>: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M<sub>5</sub> Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use DisorderAaron T Garrison, Douglas L Orsi, Rory A Capstick, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 23, 2012
Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal modelsGregory J Digby, Meredith J Noetzel, Michael Bubser, et al.
ACS Chemical Neuroscience|December 11, 2024
Discovery of VU0467319: an M<sub>1</sub> Positive Allosteric Modulator Candidate That Advanced into Clinical TrialsMichael S Poslunsey, Michael R Wood, Changho Han, et al.
ACS Chemical Neuroscience|June 6, 2026
Discovery of VU6053371/BI03738809: A First-in-Class Selective and CNS-Penetrant mGlu<sub>3</sub> Positive Allosteric Modulator (PAM) with Efficacy in a Preclinical Cognition ModelCaleb A Jones, Renn A Duncan, Kristen M Gilliland, et al.
Bioorganic & Medicinal Chemistry Letters|June 29, 2019
SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M<sub>4</sub> PAMsTrevor C Chopko, Changho Han, Alison R Gregro, et al.
Neuron|May 5, 2015
Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR CurrentsJerri M Rook, Zixiu Xiang, Xiaohui Lv, et al.
Science (New York, N.Y.)|May 6, 2003
Mutations in dynein link motor neuron degeneration to defects in retrograde transportMajid Hafezparast, Rainer Klocke, Christiana Ruhrberg, et al.
Hepatology Communications|September 25, 2022
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensusAshika D Maharaj, John Lubel, Eileen Lam, et al.
Pageof 66

Showing results (641-650 of 651) with videos related to

Sort By:
Pageof 66
ACS Chemical Neuroscience|January 25, 2026
Discovery of VU6025733 (AG06827): A Highly Selective, Orally Bioavailable, and Structurally Distinct M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust <i>In Vivo</i> EfficacyAlison R Gregro, Charlotte Park, Madeline F Long, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 17, 2000
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-AC Reavill, S G Taylor, M D Wood, et al.
Journal of Medicinal Chemistry|April 13, 2022
Development of <b>VU6019650</b>: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M<sub>5</sub> Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use DisorderAaron T Garrison, Douglas L Orsi, Rory A Capstick, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 23, 2012
Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal modelsGregory J Digby, Meredith J Noetzel, Michael Bubser, et al.
ACS Chemical Neuroscience|December 11, 2024
Discovery of VU0467319: an M<sub>1</sub> Positive Allosteric Modulator Candidate That Advanced into Clinical TrialsMichael S Poslunsey, Michael R Wood, Changho Han, et al.
ACS Chemical Neuroscience|June 6, 2026
Discovery of VU6053371/BI03738809: A First-in-Class Selective and CNS-Penetrant mGlu<sub>3</sub> Positive Allosteric Modulator (PAM) with Efficacy in a Preclinical Cognition ModelCaleb A Jones, Renn A Duncan, Kristen M Gilliland, et al.
Bioorganic & Medicinal Chemistry Letters|June 29, 2019
SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M<sub>4</sub> PAMsTrevor C Chopko, Changho Han, Alison R Gregro, et al.
Neuron|May 5, 2015
Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR CurrentsJerri M Rook, Zixiu Xiang, Xiaohui Lv, et al.
Science (New York, N.Y.)|May 6, 2003
Mutations in dynein link motor neuron degeneration to defects in retrograde transportMajid Hafezparast, Rainer Klocke, Christiana Ruhrberg, et al.
Hepatology Communications|September 25, 2022
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensusAshika D Maharaj, John Lubel, Eileen Lam, et al.
Pageof 66